Loofman is out makin' Jugs!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is from the company website and may give you some insight concerning your question.
https://www.matinasbiopharma.com/mat9001
Jmo
Loofman
18.6% of the authorized shares traded today. That’s mighty impressive! With volume comes price?
Jmo
Loofman
You got your $1 +today. I’m looking For more!
Jmo
Loofman
Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001 Providing Protection Through 2033
GlobeNewswireOctober 18, 2018, 8:00 AM EDT
BEDMINSTER, N.J., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 10,058,521 entitled, “Omega-3 pentaenoic acid compositions and methods of use” to the Company. The issued patent provides additional intellectual property protection for MAT9001, Matinas’ proprietary prescription-only omega-3 fatty acid-based composition under development for the treatment of cardiovascular and metabolic conditions, through 2033.
The issued patent claims cover the Company’s proprietary methods relating to reducing triglyceride levels, total cholesterol, VLDL-cholesterol or apolipoprotein C-III by administering a pharmaceutical composition comprising omega-3 fatty acids comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA).
“Recent developments in the cardiovascular space have placed renewed focus on MAT9001, our proprietary and purposefully designed omega-3 product. Over the past few years, we continued to be diligent in the prosecution of important intellectual property covering our MAT9001 product and the ongoing expansion of our intellectual property portfolio is an integral aspect of our development strategy. Given the clinical data generated from a head-to-head study of MAT9001 demonstrating superiority versus Vascepa® (icosapent ethyl) in reducing triglycerides, total and non-HDL cholesterol, apolipoproteins and PCSK9 levels, we are very excited about the prospects for our potential best-in-class drug in this emerging drug class. We are committed to further exploring a variety of interesting and value-creating opportunities for the development and ultimate commercialization of MAT9001,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas.
MAT9001 is comprised of docosapentaenoic acid (DPA), a potent but less prevalent omega-3 fatty acid with very unique properties, and other omega-3 fatty acids. MAT9001 was developed based on the newest scientific advancements in the field, incorporating and building upon the knowledge of almost 40 years of scientific research in the omega-3 discipline. Matinas BioPharma is developing MAT9001 for therapeutic applications in the cardiovascular and metabolic fields.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative medicines using its lipid nano-crystal (LNC) platform delivery technology. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate small molecules, oligonucleotides, vaccines and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable.
The Company's lead anti-fungal product candidate, MAT2203, positions Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary LNC formulation technology.
In addition, the Company is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoproteins and PCSK9 levels.
For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.
Investor Contact
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (833) 475-8247
Email: mtnb@jtcir.com
Media Contact
Eliza Schleifstein
Scient Public Relations
Phone: +1 (917) 763-8106
Email: eliza@scientpr.com
Source: Matinas BioPharma Holdings, Inc.
MTNB is definitely gaining attention...
Especially if MAT9001 is a better drug than Amarin’s candidate!
Jmo
Loofman
$1.22 high in premarket says a lot!
Jmo
Loofman
Today’s volume is significant. I’m guessing the company has been selling some into the news, but it’s clear that more shares are being bought up in a big way.
Jmo
Loofman
I’m expecting this to make a significant run better than Amarin’s recent amazing run.
Confirmation and approval for MAT9001 could propel the stock price 10-30x it’s current value imo.
$20 a share would be a crazy good pay day for this stock!
Jmo
Loofman
Empty bottles of...
Old Loofman’s Pure Kentucky Korn Licker are a great alternative!
Just remove the kork, Wiff the vapors, spin the bottle and let the vision appear in the moment.
Jmo
Loofman
Wook. Profit! Eom
IMO, It doesn’t seem right that I could sell at $8.56 and then buy back the shares at $7.04 when there was no glaring negatives to the quarterly report along with an upgrade with a $11.00 target! All this in less than 24 hours. I’ll take it that’s for sure and I look forward to playing the swings as we advance towards that $11 in the near term.
Jmo
Loofman
Not your fault Wook. I do recommend you start cleaning up your rocket tools.
We go up.
Jmo
Loofman
I’ll probably average down starting in mid 7’s if it shows.
Jmo
Loofman
Cheynew...
It’s been working very well for me. Ten years of losses are greatly reduced.
Sold a bunch near $9 in after hours. Totally a nice surprise!
Now to be patient and buy low again.
Jmo
Loofman
Good luck with TD. It’s been having server problems today.
Loofman
IMO, buy in small quantities, dollar cost average on down moves. Use a company like Robinhood for trading. $0 cost trading. You can buy any size order. I’ve used it for a couple of years. $10 mo for margin acct if needed.
It’s a great way to trade in and out of stocks like CDMO.
Jmo
Loofman
El CID...El CID...El CID!!!
Next amazing vision of grandeur please!
Jmo
Loofman
And...
XYZ!
I found an undocumented immigrant to fuel the space-like vehicle in your absence. So far he’s only gotten it to a near miss of an Airbus at 36,000 feet. Sure could use your expertise on how to git this CDMO SHIP at least to the ISS!
Jmo
Loofman
The Great ElSid. Supreme prognosticator. Man with reason. All around good guy.
I just put my Loofman prognastication jug away. I bow to the master.
Buy low sell high is workin’ real good-like fer Old Loofman.
Jmo
I nominate you, KU, to be the 8th board member! You would be the perfect liaison to get to the core of all goings on at Avid by being our voice! Your wit and saviness and knowledge would surely give us the direction we need to recoup our losses. It will inspire affective change in leadership and help us see future opportunities to short and buy CDMO from your keen sleuthing. I support KU4US! Please show your support for KU by posting here and often! CDMO and it’s shareholders need this!
JMO
Loofman
I’m enjoying the CDMO ride real much like. So much that me and the missus got us one of them fancy new mobile type wreckreational vehicles fer our new abode. It’s a nice ride and hope hope you will enjoy it too!
Jmo
Loofman
ElSid... love your predictions...
but, could you be just a bit more optimistic? $6 is nice, 6.20 and beyond looks nicer.
Jmo
Loofman
And away we go? Roller coasters are fun if you know when to get on and off.
I think $1 bil. market cap is achievable and sooner than later. There is finally some money behind this here stock and some credible folks who know how to make more out of it now.
Jmo
Loofman
Dollar cost averaging...
Sell the spikes and buy back the dips on consolidation.
Volitility can be your friend.
As Loofman once said,
“consume vast quantities of Pure Kentucky Korn Licker and walk the straight line!”
Jmo
Loofman
Looks like healthy consolidation after a big run up in share price over a short time frame to me.
Moderate volume. I think we’re fine.
Jmo
Loofman
I think Loofman might be getting a new still and a new shack because of CDMO!
Getting ever so much closer to making a profit since my initial investment in 2007.
I hope all you fine men and women who have hung in thar all these years are feelin’ a smite bit finer too!
jmo
Loofman
That’s the nicest thing you’ve said in some time. I knew you had a soft spot for cdmo!
I’m happy because you’re happy and that makes everybody happy. Add in a little Korn licker, we all will be euphoric!
Happy Friday!
Jmo
Loofman
It’s been a nice couple of months Golfho.
I would like a similar retrace. I did a bit of selling in the mid 5’s and would love to reload as well.
Hope you do keep up. You deserve it.
Jmo
Loofman
I know what you mean Bungler. Stranger things have happened.
I hope you recover.
Loofman
2 million shares traded in the first hour. That’s pretty exciting.
$5 is a magic number for institutional buying.
jmo
Loofman
Loofman and Tessi May are back together and are very happy. I’m hoping we C D some M O nice upticks with this here stock!
It’s been a long time coming my long friends.
Loofman
Avid feels like a real company now
Break even sounds realistic in 2019.
Feeling much more confident.
Jmo
Loofman
Volten...
Nothing wrong with that, but you probably haven’t tried Old Loofman’s Pure Kentucky Korn Licker.
It gits you thar and heps you see the stars shine bright in the middle of the night.
Go CDMO and don’t fergit to take a profit!
Jmo
Loofman
We’re moving on up...
to the north side, where riches and and shareholders stride side by side!
Jmo
Loofman
Nice to see we are past $4.60!
Now it’s starting to feel like $5.00 May be our next target.
Stay above that and we start attracting a few more funds and
Pure Kentucky Korn Licker consumers!
Jmo
Loofman
No whammy prayers being lifted up!
Prayers also for a transparent company, managed by people with vision and expertise to guide a promising cdmo to prosperity for all who believe.
Jmo
Loofman
IMO, no...
but I believe positive gains are very possible. So far so good for me. I hope everyone who continues to hang in there with this, appreciates appreciation. No longer do I see infinity and beyond. I do see things more realistically now as I consume mass quantities of Old Loofman’s Pure Kentucky Korn Licker.
Jmo
Loofman
What? I’d be out in a yacht drinkin’ Old Loofman’s Special Reserve Pure Kentucky Korn Licker if’n I had that much money! I ain’t even got no old shack no more.
I’m more of a 300 share per trade kind of feller.
GO CDMO
JMO
LOOFMAN
Welcome. The ibox is run by one kick-arse person!
Jmo
Loofman